ADMA
Adma Biologics, Inc.
A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.
CUSIP: 000899104HealthcareUS2 holders
Total Value
$17.16M
Total Shares
2.05M
Net Share Change
-71.0K
Activity
1 selling
Investor
Value
Shares
Weight
Change
